Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Authors: Matthias G Hautmann, Matthias Hipp, Oliver Kölbl

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Background and Purpose

Over the last years an increasing incidence of Clostridium difficile-associated diarrhea (CDAD) has been reported. Especially haematology-oncology patients are at risk of developing CDAD.
The aim of this analysis is to determine the incidence of CDAD in radiooncological patients and to find out what relevance CDAD has for the feasibility of the radiooncological treatment, as well as to detect and describe risk factors.

Patients and Methods

In a retrospective analysis from 2006 to 2010 34 hospitalized radiooncological patients could be identified having CDAD. The risk factors of these patients were registered, the incidence was calculated and the influence on the feasibility of the radiooncological therapy was evaluated. Induced arrangements for prophylaxis of CDAD were identified and have been correlated with the incidence.

Results

The incidence of CDAD in our collective is 1,6%. Most of the patients suffering from a CDAD were treated for carcinoma in the head and neck area. Common risk factors were antibiotics, proton pump inhibitors, cytostatic agents and tube feeding.
Beside a high rate of electrolyte imbalance and hypoproteinemia a decrease of general condition was frequent. 12/34 patients had a prolonged hospitalization, in 14/34 patients radiotherapy had to be interrupted due to CDAD. In 21 of 34 patients a concomitant chemotherapy was planned. 4/21 patients could receive all of the planned cycles and only 2/21 patients could receive all of the planned cycles in time.
4/34 patients died due to CDAD. In 4/34 patients an initially curative treatment concept has to be changed to a palliative concept.
With intensified arrangements for prophylaxis the incidence of CDAD decreased from 4,0% in 2007 to 0,4% in 2010.

Conclusion

The effect of CDAD on the feasibility of the radiotherapy and a concomitant chemotherapy is remarkable. The morbidity of patients is severe with a high lethality.
Reducing of risk factors, an intense screening and the use of probiotics as prophylaxis can reduce the incidence of CDAD.
Appendix
Available only for authorised users
Literature
1.
Vaishnavi C: Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010, 131: 487-499.PubMed
2.
Hookman P, Barkin JS: Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009, 15: 1554-1580. 10.3748/wjg.15.1554.PubMedCentralCrossRefPubMed
3.
Reichardt C, Chaberny IF, Kola A, Mattner F, Vonberg RP, Gastmeier P: [Dramatic increase of Clostridium difficile-associated diarrhea in Germany: has the new strain PCR-ribotype 027 already reached us?]. Dtsch Med Wochenschr. 2007, 132: 223-228. 10.1055/s-2007-959314.CrossRefPubMed
4.
Koh TH, Tan AL, Tan ML, Wang G, Song KP: Epidemiology of Clostridium difficile infection in a large teaching hospital in Singapore. Pathology. 2007, 39: 438-442. 10.1080/00313020701444507.CrossRefPubMed
5.
DuPont HL, Garey K, Caeiro J, Jiang Z: New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008, 21: 500-507. 10.1097/QCO.0b013e32830f9397.CrossRefPubMed
6.
Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL: Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill. 2008, 13:
7.
Thomas C, Stevenson M, Riley TV: Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003, 51: 1339-1350. 10.1093/jac/dkg254.CrossRefPubMed
8.
Kaier K, Frank U: Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note. Antimicrob Agents Chemother. 2009, 53: 4574-4575. 10.1128/AAC.00772-09.PubMedCentralCrossRefPubMed
9.
Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC, Song IS: Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010, 16: 3573-3577. 10.3748/wjg.v16.i28.3573.PubMedCentralCrossRefPubMed
10.
Aseeri M, Schroeder T, Kramer J, Zackula R: Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008, 103: 2308-2313. 10.1111/j.1572-0241.2008.01975.x.CrossRefPubMed
11.
Vesta KS, Wells PG, Gentry CA, Stipek WJ: Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control. 2005, 33: 469-472. 10.1016/j.ajic.2005.06.004.CrossRefPubMed
12.
Gifford AH, Kirkland KB: Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis. 2006, 25: 751-755. 10.1007/s10096-006-0220-1.CrossRefPubMed
13.
Blot E, Escande M, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC, Pouillart P: Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect. 2003, 53: 187-192. 10.1053/jhin.2002.1356.CrossRefPubMed
14.
Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R, Carlisle PS, Sparano J, Parker P, Salata RA: Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol. 1998, 9: 307-311. 10.1023/A:1008295500932.CrossRefPubMed
15.
Tai E, Richardson LC, Townsend J, Howard E, McDonald LC: Clostridium difficile Infection Among Children With Cancer. Pediatr Infect Dis J. 2011, 30: 610-612. 10.1097/INF.0b013e31820970d1.CrossRefPubMed
16.
Patyánik M, Nemeskéri C, Póti Z, Sinkó D, Pesznyák C, Király R, Kois R, Mayer A: Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?. Strahlenther Onkol. 2009, 185: 582-587. 10.1007/s00066-009-1974-z.CrossRefPubMed
17.
Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 2009, 19: 3-10. 10.1016/j.semradonc.2008.09.002.CrossRefPubMed
18.
Wolff HA, Bosch J, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF, Roedel RM, Christiansen H: High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol. 2010, 186: 262-268. 10.1007/s00066-010-2136-z.CrossRefPubMed
19.
Steinmann D, Cerny B, Karstens JH, Bremer M: Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol. 2009, 185: 682-688. 10.1007/s00066-009-1989-5.CrossRefPubMed
20.
Manikantan K, Khode S, Sayed SI, Roe J, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R: Dysphagia in head and neck cancer. Cancer Treat Rev. 2009, 35: 724-732. 10.1016/j.ctrv.2009.08.008.CrossRefPubMed
21.
Wurstbauer K, Merz F, Sedlmayer F: Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study. Strahlenther Onkol. 2009, 185: 512-516. 10.1007/s00066-009-1938-3.CrossRefPubMed
22.
Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H, Fietkau R: Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio - therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue. Early Results. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft ... [et al]. 2010
23.
Anand A, Bashey B, Mir T, Glatt AE: Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol. 1994, 89: 519-523.PubMed
24.
Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ, Munfakh N, Moon MR, Pasque MK, Lawton J, Moazami N, Damiano RJ: Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome. Ann Thorac Surg. 2007, 83: 1396-1402. 10.1016/j.athoracsur.2006.10.067.CrossRefPubMed
25.
Yamazawa K, Kanno H, Seki K, Kuzuta T, Matsui H, Sekiya S: Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. Acta Obstet Gynecol Scand. 2001, 80: 768-769.PubMed
26.
Resnik E, Lefevre CA: Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer. 1999, 9: 512-514. 10.1046/j.1525-1438.1999.99065.x.CrossRefPubMed
27.
Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW: Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010, 74: 309-318. 10.1016/j.jhin.2009.10.016.CrossRefPubMed
28.
29.
Fraunholz I, Rabeneck D, Weiss C, Rödel C: Combined-modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol. 2010, 186: 361-366. 10.1007/s00066-010-2162-x.CrossRefPubMed
30.
Platteaux N, Dirix P, Vanstraelen B, Nuyts S: Outcome after Re-Irradiation of Head and Neck Cancer Patients. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft ... [et al]. 2010
31.
Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C: Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol. 2010, 186: 374-381. 10.1007/s00066-010-2137-y.CrossRefPubMed
32.
Huguenin P, Glanzmann C, Taussky D, Lütolf UM, Schmid S, Moe K: Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. Strahlenther Onkol. 1998, 174: 397-402. 10.1007/BF03038560.CrossRefPubMed
33.
Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN: Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998, 129: 1012-1019.CrossRefPubMed
34.
35.
Beckmann GK, Hoppe F, Pfreundner L, Flentje MP: Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck. 2005, 27: 36-43. 10.1002/hed.20111.CrossRefPubMed
36.
Chopra T, Alangaden GJ, Chandrasekar P: Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010, 8: 1113-1119. 10.1586/eri.10.95.CrossRefPubMed
37.
Leung S, Metzger BS, Currie BP: Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol. 2010, 31: 313-315. 10.1086/651066.CrossRefPubMed
38.
Bese NS, Hendry J, Jeremic B: Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007, 68: 654-661. 10.1016/j.ijrobp.2007.03.010.CrossRefPubMed
39.
van den Bogaert W, van der Leest A, Rijnders A, Delaere P, Thames H, van der Schueren E: Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?. Radiother Oncol. 1995, 36: 177-182. 10.1016/0167-8140(95)01597-A.CrossRefPubMed
40.
Maciejewski B, Preuss-Bayer G, Trott KR: The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1983, 9: 321-328.CrossRefPubMed
41.
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ: Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005, 63: 667-671. 10.1016/j.ijrobp.2005.03.037.CrossRefPubMed
42.
Pignon J, Le Maître A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009, 92: 4-14. 10.1016/j.radonc.2009.04.014.CrossRefPubMed
43.
Foote: The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?. Oncologist. 1998, 3: 365-368.PubMed
44.
Ho KF, Swindell R, Brammer CV: Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol. 2008, 47: 1513-1518. 10.1080/02841860701846160.CrossRefPubMed
45.
Pépin J, Saheb N, Coulombe M, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005, 41: 1254-1260. 10.1086/496986.CrossRefPubMed
46.
Miller K, Fraser T: Q: What is the role of probiotics in the treatment of acute Clostridium difficile-associated diarrhea?. Cleve Clin J Med. 2009, 76: 391-392. 10.3949/ccjm.76a.08112.CrossRefPubMed
47.
Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008, CD004611-
48.
Segarra-Newnham M: Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother. 2007, 41: 1212-1221. 10.1345/aph.1K110.CrossRefPubMed
49.
Monaghan T, Boswell T, Mahida YR: Recent advances in Clostridium difficile-associated disease. Gut. 2008, 57: 850-860.PubMed
Metadata
Title
Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?
Authors
Matthias G Hautmann
Matthias Hipp
Oliver Kölbl
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-89

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

The interaction between different types of activated RAW 264.7 cells and macrophage inflammatory protein-1 alpha

Research

Technology assessment of automated atlas based segmentation in prostate bed contouring

Research

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

Research

Fast IMRT by increasing the beam number and reducing the number of segments

Commentary

Apoptosis induction and tumor cell repopulation: The yin and yang of radiotherapy

Research

Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM)